FPF
ALXN

FNY Partners Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

FNY Partners Fund’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-600
Closed -$71K – 518
2017
Q4 		$71K Buy
+600
New +$73.1K 0.01% 230
2017
Q3 		– Sell
-251
Closed -$30K – 754
2017
Q2 		$30K Sell
251
-249
-50% -$29K 0.01% 317
2017
Q1 		$60K Buy
500
+300
+150% +$38.7K 0.01% 660
2016
Q4 		$24K Buy
+200
New +$24.5K ﹤0.01% 369

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

FNY Partners Fund's ALXN Position: Q1 2018 in Review

FNY Partners Fund sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 600 shares — an estimated $71K sold.

FNY Partners Fund first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $71K in Q4 2017. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • FNY Partners Fund reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • FNY Partners Fund sold 600 Alexion Pharmaceuticals shares in Q1 2018, an estimated $71K.
  • FNY Partners Fund first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • FNY Partners Fund's Alexion Pharmaceuticals position peaked at $71K in Q4 2017.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.